Table 3.
Differences in healthcare disruption and health-related quality of life by patient characteristics
| Decided not to attend an in-person general medical appointment | Decided not to attend an in-person cancer care appointment | Decided not to seek emergency/urgent care | Participated telehealth | Low HRQOL (FACT G7≤13) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n/N (%) | P-value | n/N (%) | P-value | n/N (%) | P-value | n/N (%) | P-value | n/N (%) | P-value | |
| Sex | NS | NS | NS | <0.0001* | <0.0001* | |||||
| Males | 1687/1772 (95.2) | 1227/1346 (91.2) | 270/414 (65.2) | 2248/4096 (54.9) | 522/4093 (12.8) | |||||
| Females | 2500/2612 (95.7) | 1681/1846 (91.1) | 477/676 (70.6) | 3277/5513 (59.4) | 915/5478 (16.7) | |||||
| Race/ethnicity | <0.0001* | <0.0001* | <0.0001* | NS | NS | |||||
| Non-Hispanic White | 3443/3554 (96.9) | 2397/2574 (93.1) | 570/782 (73.0) | 4542/7923 (57.3) | 1164/7882 (14.8) | |||||
| Non-Hispanic Non-Hispanic Black | 173/177 (97.7) | 126/132 (95.5) | 33/43 (76.7) | 208/369 (56.4) | 53/366 (14.5) | |||||
| Non-Hispanic, all other races | 123/127 (96.9) | 91/98 (92.9) | 36/43 (83.7) | 163/272 (59.9) | 35/7882 (12.9) | |||||
| Hispanic, any race | 369/447 (82.6) | 229/322 (71.1) | 92/205 (44.9) | 523/878 (59.6) | 157/887 (17.7) | |||||
| Age | NS | NS | NS | NS | <0.0001* | |||||
| <65 | 1772/1869 (94.8) | 1266/1402 (60.3) | 372/535 (69.5) | 58.7 (2592/4413) | 776/4397 (17.7) | |||||
| >=65 | 2438/2538 (96.1) | 1633/1811 (91.8) | 379/559 (67.8) | 56.4 (2954/5242) | 675/5221 (12.9) | |||||
| Cancer Types | 0.19 | 0.76 | 0.08 | 0.94 | 0.25 | |||||
| Hematological malignancies | 661/699 (94.6) | 490/540 (90.7) | 106/169 (62.7) | 804/1396 (57.6) | 223/1390 (16.0) | |||||
| Solid tumor/other | 3526/3685 (95.7) | 2418/2652 (91.2) | 641/921 (69.6) | 4721/8213 (57.5) | 1214/8181(14.8) | |||||
| Cancer stage | <0.0001* | <0.0001* | <0.0001* | <0.0001* | <0.0001* | |||||
| Non-metastatic | 3319/3534 (94.4) | 2186/2470 (88.5) | 574/917 (62.6) | 4115/7433 (55.4) | 1030/7393 (14.0) | |||||
| Metastatic | 868/868 (100) | 722/722 (100) | 173/173 (100) | 1410/2176 (64.8) | 407/2178 (18.7) | |||||
| Health insurance type | <0.0001* | <0.0001* | 0.0001* | NS | <0.0001* | |||||
| Managed care | 1960/2057 (95.3) | 1358/1493 (91.0) | 369/532 (69.4) | 2769/4833 (57.3) | 715/4816 (14.9) | |||||
| Medicare | 2073/2138 (97.0) | 1438/1539 (93.4) | 328/456 (71.9) | 2516/4401 (57.2) | 625/4384 (14.3) | |||||
| Medicaid/Other governmental | 8995 (93.7) | 6271 (87.3) | 23/31 (74.2) | 132/209 (63.2) | 20/47 (42.6) | |||||
| Other | 65/94 (69.2) | 50/89 (56.2) | 27/71 (38.0) | 108/166 (65.1) | 77/324 (23.8) | |||||
| Location | <0.0001* | <0.0001* | <0.0001* | 0.003* | 0.003* | |||||
| Miami/Houston metro area | 1368/1545 (88.5) | 847/1101 (76.9) | 262/560 (46.8) | 2027/3383 (59.9) | 473/3368 (14.0) | |||||
| Non-metro area in TX/FL | 1107/1123 (98.6) | 742/768 (96.6) | 180/219 (82.2) | 1486/2611 (56.9) | 374/2303 (14.4) | |||||
| Outside of TX/FL | 1648/1652 (99.8) | 1276/1280 (99.7) | 297/303 (98.0) | 1936/3458 (56.0) | 580/3447 (16.8) | |||||
| ADI | <0.0001* | <0.0001* | <0.0001* | <0.0001* | 0.003* | |||||
| 1–20 | 1105/1189 (92.9) | 730/864 (84.5) | 163/322 (50.6) | 1524/2482 (61.4) | 319/2467 (12.9) | |||||
| 21–40 | 1276/1351 (94.5) | 897/988 (90.8) | 241/356 (67.7) | 1760/2963 (59.4) | 434/2945 (14.7) | |||||
| 41–60 | 917/935 (98.1) | 652/682 (95.6) | 194/231 (84.0) | 1161/2133 (54.4) | 340/2131 (16.0) | |||||
| 61–80 | 566/581 (97.4) | 405/427 (94.9) | 96/122 (79.7) | 706/1292 (54.6) | 221/1291 (17.1) | |||||
| 81–100 | 323/328 (98.5) | 224/231 (97.0) | 53/59 (89.8) | 374/739 (50.6) | 123/737 (16.7) | |||||
*
p<0.006 (0.05/8) is accepted as statistically significant after Bonferroni correction.
ADI: area deprivation index, FACT G7: Functional Assessment of Cancer Therapy- General- 7 Item Version, HRQOL: health-related quality of life, NS: not significant